MARKET

OYST

OYST

OYSTER POINT PHARMA, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

28.40
-0.72
-2.47%
After Hours: 28.40 0 0.00% 16:00 07/02 EDT
OPEN
29.41
PREV CLOSE
29.12
HIGH
29.65
LOW
27.87
VOLUME
62.97K
TURNOVER
--
52 WEEK HIGH
41.37
52 WEEK LOW
13.26
MARKET CAP
713.42M
P/E (TTM)
-10.3108
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average OYST stock price target is 66.67 with a high estimate of 75.00 and a low estimate of 60.00.

EPS

OYST News

More
Is Oyster Point Pharma, Inc. (OYST) A Good Stock To Buy?
Insider Monkey · 06/01 16:39
How Oyster Point (OYST) Stock Stands Out in a Strong Industry
Oyster Point (OYST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Zacks · 05/28 13:07
3 Top Pharma Stocks to Buy Right Now
Healthcare investors can look past the development risk. Global Blood Therapeutics (NASDAQ: GBT) crushed analyst estimates when it reported its first-quarter results on May 6. In its first full quarter on the market, Global Blood's sickle cell disease drug O
Motley Fool · 05/24 16:25
Oyster Point Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
PRINCETON, N.J., May 19, 2020 -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of.
GlobeNewswire · 05/19 22:08
CODX, FTCH among premarket losers
Seeking Alpha - Article · 05/15 13:17
The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14)
Benzinga · 05/15 11:49
Oyster Point Pharma Announces Pricing of an Upsized Offering of Common Stock
GlobeNewswire · 05/15 07:02
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12)
Benzinga · 05/13 11:40

Industry

Biotechnology & Medical Research
+0.68%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About OYST

Oyster Point Pharma, Inc. is a clinical stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its lead product candidate is OC-01 (varenicline), a selective nicotinic acetylcholine receptor (nAChR) agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease (DED). OC-01’s is a mechanism of action, which is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the TPP and stimulating the glands and cells responsible for natural tear film production. It is sprayed into the anterior portion of the nasal cavity, and stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.
More

Webull offers kinds of Oyster Point Pharma Inc stock information, including NASDAQ:OYST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OYST stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OYST stock methods without spending real money on the virtual paper trading platform.